ITMR Itamar Medical

Itamar Medical to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

Itamar Medical to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

CAESAREA, Israel, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that Gilad Glick, President and Chief Executive Officer of Itamar Medical, will present at the Ladenburg Thalmann 2019 Healthcare Conference in New York, NY, on Tuesday, September 24, 2019 at 12:00 PM ET.

A live and archived webcast of the presentation will be available on the investor section of the Company’s website at: .

For more information about the conference, or to schedule a one-on-one meeting with Itamar Medical’s management, please contact your Ladenburg Thalmann representative.

About Itamar Medical Ltd.

Itamar Medical is engaged in research, development, sales and marketing of non-invasive medical devices for the diagnosis of respiratory sleep disorders and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market. The Company offers a Total Sleep Solution™ to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare costs. Its flagship PAT®-based product, the WatchPAT™ device, is a home-use diagnostic device for sleep breathing disorders. Its digital health platform, including CloudPAT™ and SleePATh™, facilitates seamless and complete care pathway management in a complex environment. It also offers the EndoPAT™ system, an FDA-cleared device to test endothelial dysfunction and to evaluate the risk of heart disease and other cardiovascular diseases. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit .

Contact:

David Carey

Lazar Partners Ltd.



212-867-1762

Eran Gabbai, Partner

Galbert-Kahana Investor Relations and Public Relations

Tel:

* The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release

EN
10/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Itamar Medical

 PRESS RELEASE

Itamarâ„¢ Medical to Report Third Quarter 2019 Financial Results and H...

Itamar™ Medical to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 26, 2019 CAESAREA, Israel, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that it will report its unaudited financial results for the third quarter of 2019 before the U.S. marke...

 PRESS RELEASE

Itamar Medical Announces Blue Shield of CA and Blue Cross Blue Shield ...

Itamar Medical Announces Blue Shield of CA and Blue Cross Blue Shield Federal Employee Plan to Include WatchPAT™ in Their Policies - CMS Announces 2020 Fee Schedule  - CAESAREA, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq:  ITMR) (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep-apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, today announced that Blue Shield of California (BSC) and the Blue ...

 PRESS RELEASE

Itamar Medical Appoints Jennifer Cook, MD, FAHA, FACC, as Global Medic...

Itamar Medical Appoints Jennifer Cook, MD, FAHA, FACC, as Global Medical Director CAESAREA, Israel, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced the appointment of Jennifer Cook, MD, FAHA, FACC to the newly created position of Global Medical Director, effective immediately. In this role, D...

 PRESS RELEASE

Itamar Medical to Present at the Ladenburg Thalmann 2019 Healthcare Co...

Itamar Medical to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019 CAESAREA, Israel, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that Gilad Glick, President and Chief Executive Officer of Itamar Medical, will present at the Ladenburg Thalmann 2019 ...

 PRESS RELEASE

Itamar Medical Reports Record Second Quarter 2019 Revenues

Itamar Medical Reports Record Second Quarter 2019 Revenues - Total Second Quarter Revenues Increase 21% to $7.4 Million -  - WatchPATTM Revenues Increase 16% in the Second Quarter to $6.5 Million -  - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT -  CAESAREA, Israel, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today reported unaudited financial results for the three months and six-month ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch